# A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

> **NCT05538624** · PHASE1,PHASE2 · TERMINATED · sponsor: **Avenge Bio, Inc** · enrollment: 14 (actual)

## Conditions studied

- Neoplasm, Ovarian
- Fallopian Tube Cancer
- Primary Peritoneal Cavity Cancer
- Adenocarcinoma Ovary
- Serous Adenocarcinoma of Ovary
- Serous Adenocarcinoma of Primary Peritoneum
- Primary Peritoneal Carcinoma
- High Grade Serous Adenocarcinoma

## Interventions

- **DRUG:** AVB-001 (Dose Escalation Phase)
- **DRUG:** AVB-001 (Dose Expansion Phase)

## Key facts

- **NCT ID:** NCT05538624
- **Lead sponsor:** Avenge Bio, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-09
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-10
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sponsor Decision to close study
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05538624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05538624, "A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05538624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*